Elevated plasma chromogranin-A concentrations in prostatic carcinoma. uri icon

Overview

abstract

  • Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.

publication date

  • August 1, 1991

Research

keywords

  • Carcinoma
  • Chromogranins
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 0026355799

Digital Object Identifier (DOI)

  • 10.1016/s0022-5347(17)37793-5

PubMed ID

  • 1856931

Additional Document Info

volume

  • 146

issue

  • 2